Open AccessA Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus–Exposed Uninfected Infants
Author(s) -
Sylvia M LaCourse,
Barbra A. Richardson,
John Kinuthia,
Alex J Warr,
Elizabeth MalecheObimbo,
Daniel Matemo,
Lisa M Cranmer,
Jerphason Mecha,
Jaclyn N Escudero,
Thomas R. Hawn,
Grace JohnStewart
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa827
Subject(s) - medicine , isoniazid , tuberculosis , randomized controlled trial , tuberculin , mycobacterium tuberculosis , interferon gamma release assay , adverse effect , confidence interval , hazard ratio , clinical endpoint , immunology , latent tuberculosis , pathology
Human immunodeficiency virus (HIV)-exposed uninfected (HEU) infants in endemic settings are at high risk of tuberculosis (TB). For infants, progression from primary Mycobacterium tuberculosis (Mtb) infection to TB disease can be rapid. We assessed whether isoniazid (INH) prevents primary Mtb infection.